Trial of Oral SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder

Summary

This is a randomized, double-blind, placebo-controlled study of SNC-102 in adult subjects with cPTSD, added to pre-existing treatment that includes prazosin with or without other psychotropic drugs. Subjects will be treated with SNC-102 tablets or matching placebo on a BID basis for 8 weeks. Subjects will be evaluated for the symptoms of combat-related posttraumatic stress disorder (cPTSD) as measured by the Clinician Administered PTSD Scale (CAPS-5), compared with the response to placebo.

Timeline

Start

2016-06

Primary completion

2017-06

Completion

2017-08

Outcome

Outcome not reported

Stopped: “Insufficient”

Drugs

Indications